|
業務類別
|
Biotechnology |
|
業務概覽
|
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors. |
| 公司地址
| 100 Park Avenue, 23rd Floor, New York, NY, USA, 10017 |
| 電話號碼
| +1 646 677-3870 |
| 傳真號碼
| +1 845 818-3588 |
| 公司網頁
| https://www.actiniumpharma.com |
| 員工數量
| 25 |
| Mr. Sandesh Seth |
Chief Financial Officer, Chairman of the Board and Chief Executive Officer |
美元 733.20K |
13/02/2026 |
|
|
| Mr. Richard I. Steinhart |
Independent Director |
30/03/2026 |
| Mr. Sandesh Seth |
Chief Financial Officer, Chairman of the Board and Chief Executive Officer |
13/02/2026 |
| Dr. David Nicholson, Pd.D |
Lead Independent Director |
30/03/2026 |
| Dr. Ajit S. Shetty, PhD |
Independent Director |
30/03/2026 |
| Dr. Jeffrey W. Chell, M.D. |
Independent Director |
30/03/2026 |
| Dr. June S. Almenoff, F.A.C.P.,M.D.,PhD |
Independent Director |
30/03/2026 |
|
|
|
|
